Ken Griffin’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2015
Q2
Sell
-11,200
Closed -$1.09M 9427
2015
Q1
$1.09M Buy
11,200
+2,800
+33% +$296K ﹤0.01% 3815
2014
Q4
$779K Buy
8,400
+3,500
+71% +$276K ﹤0.01% 4101
2014
Q3
$337K Sell
4,900
-9,900
-67% -$709K ﹤0.01% 5123
2014
Q2
$1.55M Sell
14,800
-7,500
-34% -$638K ﹤0.01% 2992
2014
Q1
$1.85M Buy
22,300
+17,100
+329% +$1.58M ﹤0.01% 2735
2013
Q4
$337K Buy
+5,200
New +$309K ﹤0.01% 4482

Ken Griffin's GEVA Position: Q1 2015 in Review

Ken Griffin sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q1 2015, closing a stake of 11,940 shares — an estimated $1.26M sold.

Ken Griffin first reported a position in GEVA in Q4 2013 and held it in 5 quarters. The position peaked at $2.58M in Q1 2014. 130 funds tracked by Wall St. Rank hold GEVA as of Q1 2015.

  • Ken Griffin reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q1 2015 after selling out during the quarter.
  • Ken Griffin sold 11,940 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q1 2015, an estimated $1.26M.
  • Ken Griffin first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q4 2013 and held it in 5 quarters.
  • Ken Griffin's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $2.58M in Q1 2014.
  • 130 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q1 2015.

Based on Citadel Advisors's 13F filing for Q1 2015, filed 15 May 2015.